Avandia Marked More Dangerously Than Peer Drug

A study recently published in the Archives of Internal Medicine found that Avandia, a type 2 diabetes drug, may be "riskier than Actos, another drug in the same class," according to an article by U.S. News & World Report.According to an article published in the New England Journal of Medicine, a link has been discovered between consuming Avandia and developing heart disease and heart failure. While the article received much attention and was followed by several additional studies confirming the alleged side effects, the drug remained on the market following a May 2007 Food and Drug Administration health advisory. Now, however, patients who consume Avandia may be switching to its counterpart, Actos, as both are part of the drug class known as thiazolidinediones, but Actos is apparently less risky especially among elderly diabetic patients aged 65 years of age and older.The American Heart Association (AHA), makers of Avandia GlaxoSmithKline and the biotechnology firm Amgen funded the study. The study reported that close to 28,000 of the diabetic patients who consumed either Avandia or Actos (approximately 50.3 percent of this study group consumed Avandia and the othe
Bookmark to:

Full Article At: KnowHow-Now.com Articles

Bookmark to: